Moderna grows stronger in the land of the rising sun. The American biotech company and the Japanese Takeda have announced the transfer of the marketing authorization for the vaccine against Covid-19 developed by the North American company, named Spikevax TM (mRNA-1273), from Takeda to Moderna in Japan from August 1, 2022.
Moderna will assume responsibility for all Spikevax activities, including importation, local regulation, development, quality control and marketing. Takeda will continue to provide distribution support under the current national vaccination campaign during a transition period. Both companies will be in charge of ensuring the correct execution of the operations associated with this transfer.
“We thank Takeda for their support and partnership in bringing our vaccine to Japan over the past two years and for helping play a key role in addressing the pandemic across the country,” said Stéphane Bancel, CEO of Moderna. “We are happy to take this important step as we continue to build and strengthen our own business organization in Japan, and look forward to continuing our partnership with Takeda in 2022.”
Moderna tripled its profit in the first quarter of 2022 compared to the same period in 2021, to 3,657 million dollars
“We are proud to have been able to support the early public health response to the pandemic by using Takeda’s network to provide Moderna’s Covid-19 vaccine to the people of Japan,” said Gary Dubin, president of the unit. of Takeda’s global vaccines. “We will continue to provide transition distribution support to ensure continuity of supply,” adds Dubin.
In the ten years since its inception, Moderna has transformed from a scientific research-stage company promoting programs in the field of messenger RNA (mRNA) to a company with a diverse clinical portfolio of vaccines and therapies across seven modalitiesa broad portfolio of intellectual property in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing facility that enables rapid clinical and commercial-scale production.
Moderna tripled its profit in the first quarter of 2022 compared to the same period in 2021, to 3,657 million dollars, according to the latest published results. In the first quarter of 2021, Moderna recorded its first positive result. The figures from then and the last published contrast with the accumulated until March 2020, when the bioetch recorded losses of 124 million dollars.
Moderna’s total revenue in the first quarter of 2022 was $6.066 million, compared to 1,937 million dollars in the same period of the previous year. Of this amount, product sales were 5,925 million dollars, compared to 1,733 million dollars accumulated until March 2021.
–
